IRIS Accounts Production v24.1.9.2 14230373 director 1.8.23 31.3.24 31.3.24 0 0 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh142303732023-07-31142303732024-03-31142303732023-08-012024-03-31142303732022-07-11142303732022-07-122023-07-31142303732023-07-3114230373ns15:EnglandWales2023-08-012024-03-3114230373ns14:PoundSterling2023-08-012024-03-3114230373ns10:Director12023-08-012024-03-3114230373ns10:PrivateLimitedCompanyLtd2023-08-012024-03-3114230373ns10:SmallEntities2023-08-012024-03-3114230373ns10:AuditExempt-NoAccountantsReport2023-08-012024-03-3114230373ns10:SmallCompaniesRegimeForDirectorsReport2023-08-012024-03-3114230373ns10:SmallCompaniesRegimeForAccounts2023-08-012024-03-3114230373ns10:FullAccounts2023-08-012024-03-3114230373ns10:RegisteredOffice2023-08-012024-03-3114230373ns5:CurrentFinancialInstruments2024-03-3114230373ns5:CurrentFinancialInstruments2023-07-3114230373ns5:ShareCapital2024-03-3114230373ns5:ShareCapital2023-07-3114230373ns5:RetainedEarningsAccumulatedLosses2024-03-3114230373ns5:RetainedEarningsAccumulatedLosses2023-07-3114230373ns5:ComputerEquipment2023-08-012024-03-3114230373ns5:ComputerEquipment2024-03-3114230373ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-03-3114230373ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-07-31142303731ns10:Director12023-07-31142303731ns10:Director12022-07-11142303731ns10:Director12023-08-012024-03-31142303731ns10:Director12022-07-122023-07-31142303731ns10:Director12024-03-31142303731ns10:Director12023-07-31
REGISTERED NUMBER: 14230373 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS

FOR THE PERIOD 1 AUGUST 2023 TO 31 MARCH 2024

FOR

K.A.R PHARMA LIMITED

K.A.R PHARMA LIMITED (REGISTERED NUMBER: 14230373)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE PERIOD 1 AUGUST 2023 TO 31 MARCH 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


K.A.R PHARMA LIMITED

COMPANY INFORMATION
FOR THE PERIOD 1 AUGUST 2023 TO 31 MARCH 2024







DIRECTOR: Mr K Ramzi





REGISTERED OFFICE: 11 Charminster Avenue
Bournemouth
Dorset
BH9 1RP





REGISTERED NUMBER: 14230373 (England and Wales)





ACCOUNTANTS: BK Plus Limited
Chartered Accountants
Murrills House
48 East Street
Portchester
Fareham
Hampshire
PO16 9XS

K.A.R PHARMA LIMITED (REGISTERED NUMBER: 14230373)

BALANCE SHEET
31 MARCH 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 429 -

CURRENT ASSETS
Debtors 5 8,580 100
Cash at bank 2,126 -
10,706 100
CREDITORS
Amounts falling due within one year 6 10,638 -
NET CURRENT ASSETS 68 100
TOTAL ASSETS LESS CURRENT
LIABILITIES

497

100

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 397 -
SHAREHOLDERS' FUNDS 497 100

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

K.A.R PHARMA LIMITED (REGISTERED NUMBER: 14230373)

BALANCE SHEET - continued
31 MARCH 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 5 June 2024 and were signed by:





Mr K Ramzi - Director


K.A.R PHARMA LIMITED (REGISTERED NUMBER: 14230373)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD 1 AUGUST 2023 TO 31 MARCH 2024


1. STATUTORY INFORMATION

K.A.R Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover represents sales of services.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Computer equipment - 25% on cost

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was NIL (2023 - NIL).

K.A.R PHARMA LIMITED (REGISTERED NUMBER: 14230373)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 1 AUGUST 2023 TO 31 MARCH 2024


4. TANGIBLE FIXED ASSETS
Computer
equipment
£   
COST
Additions 572
At 31 March 2024 572
DEPRECIATION
Charge for period 143
At 31 March 2024 143
NET BOOK VALUE
At 31 March 2024 429

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 1,872 -
Other debtors 6,708 100
8,580 100

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Taxation and social security 9,619 -
Other creditors 1,019 -
10,638 -

K.A.R PHARMA LIMITED (REGISTERED NUMBER: 14230373)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 1 AUGUST 2023 TO 31 MARCH 2024


7. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the periods ended 31 March 2024 and 31 July 2023:

2024 2023
£    £   
Mr K Ramzi
Balance outstanding at start of period - -
Amounts advanced 49,364 -
Amounts repaid (42,756 ) -
Amounts written off - -
Amounts waived - -
Balance outstanding at end of period 6,608 -

Loans to directors are interest bearing and repayable on demand.